Plain Language Summary {#Sec01}
======================

*Clostridium difficile* (*C. difficile*) is a bacterium that often lives without causing harm in people's gut. However, when a person has antibiotic treatment for another infection, this can cause an imbalance in the normal levels of bacteria in the gut, and the *C. difficile* can grow and replace many of the normal bacteria, causing *C. difficile* infection (CDI). Symptoms include diarrhea, fever and pain. Although CDI is often mild, it can be very serious, particularly in older people, and, if untreated, can be fatal. This review looked at studies published from 2006 to 2017 to investigate patterns of CDI sickness (epidemiology) in Japan. A total of 55 studies were useful for our review and showed that, in general, CDI occurred less commonly in Japan than in Western countries. However, there was wide variation in the tests used to detect infection and the methods used to identify specific types of *C. difficile* bacteria responsible for the infections. Because of this variety, there was a difference in the reliability of the results from the different studies, which made it difficult to make comparisons between studies. However, there seemed to be consistent results showing that certain types of *C. difficile* were common in Japan. The studies were not able to tell us whether the types of *C. difficile* varied over time. More studies that use reliable high-quality tests, and greater detailed analysis in Japan to map patterns of CDI over time are needed. This would help us to understand the importance of CDI in Japan.

Introduction {#Sec1}
============

*Clostridium difficile* is the most common infective cause of nosocomial diarrhea, implicated in 20--30% of cases of antibiotic-associated diarrhea \[[@CR1], [@CR2]\]. Appropriate patient care requires rapid and accurate diagnosis to support optimal management and prevent the spread of infection. Furthermore, knowledge of specific risk factors for *C. difficile* infection (CDI) in different clinical settings is essential.

No national CDI surveillance system has been implemented in Japan, and therefore it is challenging to grasp the trend in epidemiology over time using a standardized method. A review of CDI in Asia published in 2013 found only a few molecular-typing studies providing contemporary epidemiological information \[[@CR3]\]. According to a questionnaire-based survey of 2537 hospitals in Japan in 2013, which had valid responses from 321 hospitals, CDI incidence varied between centers \[[@CR4]\], and there was little information on the specific strains causing infection.

There have been several important changes in CDI diagnosis and treatment in Japan. First, a new diagnostic kit detecting toxin A and B plus "common" antigen (glutamate dehydrogenase; GDH) became available in April 2011. Second, oral and injectable metronidazole were indicated for CDI in August 2012 \[[@CR5]\] and September 2014 \[[@CR6]\], respectively, although unlicensed use of oral metronidazole for CDI had occurred in Japan prior to 2012. Third, in 2015, the Japanese Association for Infectious Diseases and Japanese Society of Chemotherapy released guidelines for the treatment of enteric infection, in which oral metronidazole was designated as the first-line treatment for CDI \[[@CR7]\]. Vancomycin was recommended for severe cases and/or second and subsequent recurrences \[[@CR7]\].

Considering these recent changes in the diagnosis and treatment of CDI, there is a greater need to understand and update the epidemiology of CDI, the predominant strains causing the infection, and the consequences, risks and resource utilization associated with CDI in clinical settings in Japan. This literature review was undertaken to summarize published epidemiological data on CDI in Japan from January 2006 to November 2017, to describe definitions of CDI applied, molecular typing and diagnostic methods used, and key risk factors and expected outcomes.

Methods {#Sec2}
=======

The recent literature was reviewed in a systematic fashion to identify studies and reports relating to the epidemiology of CDI in Japan. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were used to inform search terms, and the literature review process was conducted using the PRISMA Checklist and PRISMA Flow diagram.

Identification {#Sec3}
--------------

Searches of MEDLINE-PubMed and EMBASE^®^ were made using the following primary search terms: *C. difficile* infection; pseudomembranous colitis; epidemiology; Japan. Secondary search terms were as follows: *C*. *difficile* diarrhea; *C*. *difficile* colitis; enterocolitis; toxic megacolon; hospital-acquired diarrhea; nosocomial diarrhea; antibiotic-associated diarrhea; incidence; Japan. The publications were limited to the English language from 1 January 2006 to 27 November 2017.

Selection {#Sec4}
---------

Identified abstracts were reviewed by a single reviewer to remove duplicates and to identify publications meeting the pre-defined inclusion and exclusion criteria. Inclusion criteria were: Japanese patients or human samples with CDI; observational or non-randomized interventional studies; cross-sectional surveys; cohort studies; case--control studies; pharmacy records or claims databases; electronic registers or electronic medical/health records; insurance or administrative claims databases studies; registry studies; prospective or retrospective studies; longitudinal or follow-up studies; and reviews. Publications were included if they reported on: CDI epidemiology (incidence/prevalence); CDI risk factors; CDI definitions; diagnostic and laboratory test methods; CDI strains; length of hospital stay (LOS); intensive care unit admission; CDI recurrence; and mortality. There was reliance on the individual publications to define CDI and no minimum (discriminatory) definition was used during the selection process. Exclusion criteria were: animal studies; in vitro studies; case reports; editorials, commentaries and letters; congress abstracts; and non-English language publications. All publications that met criteria for the review were obtained as full articles, reassessed and reviewed.

Quality Determination and Data Extraction {#Sec5}
-----------------------------------------

A single reviewer assessed the quality of each paper/study according to Oxford Centre for Evidence-Based Medicine -- Levels of Evidence \[[@CR8]\] (Enhanced Supplementary Material). As most of the captured studies did not fall strictly within a given category, references were also assessed by the same individual to ensure consistent application of the criteria across all publications.

Data from the selected studies were extracted by a single reviewer and used to populate summary tables.

Compliance with Ethics Guidelines {#Sec6}
---------------------------------

The analysis in this article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by either of the authors.

Results {#Sec7}
=======

Identification of Relevant Publications {#Sec8}
---------------------------------------

A total of 385 potential articles were identified, of which 55 were defined as relevant, after applying the pre-defined inclusion and exclusion criteria (Fig. [1](#Fig1){ref-type="fig"}). One article was an erratum \[[@CR9]\] of a previously identified study \[[@CR10]\], therefore the study was counted only once. The assigned grades of literature per relevant article are summarized in the Enhanced Supplementary Material.Fig. 1Assessment of search results to identify key papers for review and data extraction. *Asterisk* did not meet inclusion criteria in relation to study population or design (see "[Selection](#Sec4){ref-type="sec"}"). *Hash* did not include reports of: *Clostridium difficile* infection (CDI) epidemiology (incidence/prevalence); CDI risk factors; CDI definitions; diagnostic and laboratory test methods; CDI strains; length of hospital stay; intensive care unit admission; CDI recurrence; or mortality. *Dagger* one identified article was an erratum of a previously identified study, therefore the study was counted only once

Many papers were insufficiently specific: for example, several papers reported on the validation of novel *C. difficile* diagnostic assays or laboratory testing methods in Japan, but did not include clinical data. Others were excluded owing to a small sample size (*n* ≤ 8), a focus on pre-clinical evaluation of CDI testing methods, or for reporting CDI contamination in non-patient groups \[[@CR11]--[@CR15]\]. Several papers were reviews or editorials with limited relevance to Japanese CDI epidemiology \[[@CR3], [@CR16], [@CR17]\].

Incidence and Prevalence {#Sec9}
------------------------

Twenty-four papers reported data relating to the incidence and prevalence of CDI, or to *C*. *difficile*-related disease or diarrhea in Japanese cohorts (Table [1](#Tab1){ref-type="table"}). Most reports were based on retrospective chart reviews (*n* = 16), eight were prospective studies; either observational studies or randomized controlled trials (RCTs), and one was a systematic review and meta-analysis. Most of the papers described and defined CDI in terms of clinical diagnosis ('diarrhea') and laboratory findings ('toxin positivity'). The papers differed in their approach to testing for CDI: some actively investigated *C*. *difficile* colonization across cohorts whilst others tested for *C. difficile* only in patients with clinical symptoms suggestive of CDI. Testing methods also varied. Because of these differences and the heterogeneity in the patient populations examined in the publications, including hematopoietic stem cell transplant (HSCT) patients, rheumatology patients and those with *Helicobacter pylori*-positive peptic ulcer, it was not possible to examine trends over time in the incidence of CDI.Table 1Incidence and prevalence of *C. difficile*, and risk factors associated with *C. difficile* infection reported in Japanese patient populationsReferenceStudy periodStudy designPatient population*C. diff* diagnosis (*n*)*C. diff* definitionIncidencePrevalenceRisk factors for CDIAkahoshi et al. \[[@CR24]\]November 2007--May 2014Retrospective, single-center, chart review\
*n* = 308HSCT (*n* = 102 autologous; *n* = 206 allogeneic)*n* = 30\
Occurring median 7 days (range 0--36) after HSCT conditioningDiarrhea (≥ 3 loose stools/24 h) in first 100 days post HSCT\
Positive CD toxin^a^ or positive CD toxin plus GDH^b^Cumulative incidence 6.2% in HSCT population (9.2% allogeneic; 1.0% autologous)--Allogeneic HSCT, total body irradiation, stem cell source, acute leukemia, duration of neutropenia -- linked with increased risk for CDI\
Allogeneic HSCT: OR for CDI 18.6 (95% CI 2.48--139) *p* \< 0.01; duration of neutropenia ≥ 17 days in first 30 days: OR for CDI 10.4 (95% CI 2.37--46 *p* \< 0.01)Daida et al. \[[@CR31]\]July 2003--September 2012Retrospective case--control study via medical record review from a single centerPediatric patients (aged 0--19 years) admitted to hospital with cancer (*n* = 51)\
Matching case controls were selected from patients without CDI admitted to hospital within 2 months (before/after) admission for patients with CDI (*n* = 94)*n* = 51Test for *C. diff* toxins A/B^a^\
Appearance of symptoms ≥ 3 days after admission51/189 = 26.98%--Multivariable analysis of risk factors for hospital-acquired CDI: younger age is a risk factor: age 0--3 years vs. age 4--6 years, OR 0.13 (95% CI 0.03--0.59); *p* = 0.008, and vs. age ≥ 7 years, OR 0.12 (95% CI 0.03--0.45); *p* = 0.002. Prolonged neutropenia is a risk factor: OR 1.11 (95% CI 1.03--1.20); *p* = 0.008. Use of ≥ 4 antibiotics in the 60 days from diagnosis or reference date: OR 3.55 (95% CI 1.40--9.04); *p* = 0.008Furuichi et al. \[[@CR32]\]August 2012--March 2013Prospective, non-interventional cohort to assess rates of community-acquired *C. diff* colonization (single center)\
*n* = 346 childrenHealthy neonates (*n* = 95) and pediatric patients at hospital admission (*n* = 251)0 (0%) *C. diff* (asymptomatic) colonization in neonates\
Pediatric population without underlying disease: *C. diff* colonization 21.6% and 9% toxin positive colonization; vs. with underlying disease 30.8% and 23.1% (colonization and toxin-positive colonization)Cultured fecal samples positive for *C. diff* toxin A/B^b^Asymptomatic CDI\
9% toxin-positive colonization in pediatric patients with no underlying disease\
23.1% toxin-positive colonization in pediatrics with underlying disease--Risk factors for toxin-positive *C. diff* colonization: underlying disease (OR 4.17, 95% CI 1.15--15.04; *p* = 0.049); age 12--23 months (OR 4.19, 95% CI 1.52--11.52; *p* = 0.01); tube feeding (OR 24.28, 95% CI 4.70--125.34; *p* \< 0.001); toxin-positive *C. diff* (OR 8.29, 95% CI 1.87--36.84; *p* = 0.005)Hashimoto et al. \[[@CR26]\]January 1996--November 2004Retrospective chart review (single center)\
*n* = 242Living-donor liver transplant recipients (adult)Diarrhea 76/242; *C. diff* diarrhea 11/242*C. diff* diarrhea: ≥ 3 loose stools on ≥ 2 consecutive days and positive stool culture and assays for toxin A^c^ and GDH^d^11/242 *C. diff* diarrhea = 4.5%^e^--Male gender (OR 4.56; 95% CI 1.02--33.3, *p* = 0.05) and serum creatinine md/dL ≥ 1.5 (OR 16.0, 95% CI 3.85--68.3, *p* = 0.0003) predicted risk for *C. diff* diarrhea\
Intensity of antibiotic use did not predict for *C. diff* diarrheaHata et al. \[[@CR62]\]November 2007--December 2012Phase 3, multicenter, open-label RCT (assessing antibiotic prophylaxis)\
*n* = 579Colorectal surgery (colorectal cancer patients; elective laparoscopic)Rate of *C. diff* infection: oral--IV prophylaxis group 1/289; IV prophylaxis 3/290Positive test for *C. diff* toxins in patients developing enteritis/colitis/diarrhea (assay not described)Incidence rate *C. diff* toxins in oral--IV and IV groups 0.3% and 1.0%, respectively (*p* = NS between oral--IV and IV prophylaxis groups)5.2 cases/1000 patients^e^--Hikone et al. \[[@CR20]\]August 2011--September 2013Retrospective chart review of in- and outpatient samples (single center)\
*n* = 2193 samples tested for *C. diff* toxinIn- and outpatient samples tested for *C. diff*107 specimens positive for *C. diff* toxin;\
76 cases of healthcare-facility onset CDIPositive *C. diff* toxin test^b^Incidence rate 0.8 cases/10,000 patient-days\
30-day and 90-day mortality rates: 7.9% and 14.5%, respectively--Risk factors for recurrent CDI: malignant disease (OR 7.98; 95% CI 1.22--52.2; *p* = 0.03); history of ICU hospitalization (OR 49.9; 95% CI 1.01--2470; *p* = 0.049)Honda et al. \[[@CR18]\]September 2010--August 2012Retrospective chart review (single tertiary care center)\
*n* = 22,863 adult patients; and 1537 *C. diff* tests in 851 patientsCases of CDI in a non-outbreak setting126 cases diagnosed with CDI (86.5% were healthcare-facility onset CDI)Diarrhea and positive toxin assay^b^ or presence of pseudomembranous colitis^f^\
Healthcare-facility onset CDI: symptom onset \> 3 days from admission\
Community-onset CDI: symptom onset prior to or within 3 days of admissionHealthcare-facility onset CDI: 3.11 cases/10,000 patient-days\
Community-onset CDI: 0.2 cases/10,000 patient-days for CDI attributable to the study hospital\
30-day all-cause mortality in CDI cohort: 15.1%126/22,863 = 5.5 cases/1000 patients^e^--Hosokawa et al. \[[@CR25]\]January 2007--December 2008Retrospective cohort (single center)\
*n* = 201 patientsAllogeneic HSCT patients (135 unrelated cord blood; 39 unrelated bone marrow and 27 related peripheral blood stem cell)167/201 patients tested for *C. diff*\
17/201 diagnosed *C. diff* diarrhea\
*C. diff* diarrhea in: 11/135 (9%) unrelated cord blood recipients; 2/39 (6%) unrelated BMT recipients; 4/27 (16%) related PBST recipients*C. diff* diarrhea: \> 3 loose stools/24 h for 2 consecutive days and positive ELISA for *C. diff* toxin ACumulative incidence of *C. diff* diarrhea 9% at post-transplant day 100--Total body irradiation associated with reduced risk of *C. diff* diarrhea\
*C. diff* diarrhea was not a cause of any death; no recurrence of *C. diff* diarrhea after treatmentIwamoto et al. \[[@CR27]\]Two periods: March 2004--February 2006 and April 2008--December 2008Prospective observational cohort (single center)\
*n* = 1226Rheumatology inpatients54 cases of healthcare associated infection of which 2 were *C. diff* infection (1 patient in each study period)Healthcare-associated infection: developing \> 3 days after admission2/1226 in rheumatology patients (0.16%)^e^----Iwashima et al. \[[@CR44]\]April 2005--March 2008Retrospective cohort study assessing genotypic features of isolates and clinical characteristics of CDI (single center)\
*n* = 610 submitted specimensPatients with stools found positive for *C. diff* culture (n = 106; of which 35 excluded as asymptomatic carriers and *n* = 14 excluded for non-toxigenic strains)71 *C. diff* infection cases assessedPCR assessment of toxin A and B; ribotyping\
CDI: diarrhea or colitis with positive test for *C. diff* toxin B and no other enteropathogenic microorganisms\
Recurrent CDI: recurring within 2 months of previous episodeIncidence of CDIs with binary toxin-positive strains 5.6% (noted in patients with non-severe CDI)Prevalence \< 5 CDI cases/month--Kaneko et al. \[[@CR30]\]January 2006--April 2009Retrospective cohort investigating for CDI during active phase of inflammatory bowel disease (single center)\
*n* = 137Active ulcerative colitis55/137 (40.1%) tested samples were CDI positivePresence of toxin A antigen^g^ in gut lavage40.1% in a sample tested for possible CDI----Kobayashi et al. \[[@CR21]\]April 2012--September 2013Retrospective cohort study based on chart review at four teaching hospitals in JapanPatients aged ≥ 14 years with hospital-onset CDI*n* = 160 with hospital-onset CDIAccording to SHEA/IDSA 2010 guidelines, based on positive CD toxin EIA.^b^ Hospital-onset CDI: hospitalized for condition other than CDI for ≥ 2 days1.04 cases per 10,000 patient-days; 1.61 cases per 1000 admissions----Komatsu et al. \[[@CR22]\]June 2008--December 2013Single-center RCT\
*n* = 379\
Looking at efficacy of perioperative synbiotics to prevent infectious complications (particularly surgical site infection)Colorectal surgery (laparoscopic)0/168 cases *C. diff* infection in synbiotics group and 1/194 in control group\
Author reports use of synbiotics suppressed increases in potentially pathogenic *C. diff* (detected in 4% before surgery both groups; detected in 4% 7 days after surgery in synbiotic group vs. 13% control; *p* = 0.05 vs. day before surgeryGut microbiota assessed by YIF-SCAN and PCR analyses1/379 colorectal surgery patients (0.3%)^e^----Mizui et al. \[[@CR37]\]February 2010-- February 2011Retrospective study of risk factors for *C. diff* diarrhea (single center)\
*n* = 2716 patients given an injectable antibiotic\
Study also assessed impact of probioticsInpatients given antibiotics29 had *C. diff* diarrhea\
(2687 had non-*C. diff* diarrhea)\
Risk factors investigated between groups re: use of antibiotics ≥ 8 days; enteral nutrition; IV hyperalimentation; fasting, proton pump inhibitors H~2~ blockers; serum albumin ≤ 2.9 g/dL*C. diff* diarrhea; tests not defined----Risk factors for *C. diff* diarrhea were: antibiotic use ≥ 8 days (OR 4.071; 95% CICI 1.333--12.430; *p* = 0.014), IV hyperalimentation (OR 3.414; 95% CI 1.469--7.934; *p* = 0.004), PPIs (OR 3.224; 95% CI 1.421--7.315; *p* = 0.005), H~2~ blockers (OR 2.376; 95% CI 1.047--5.391; *p* = 0.039)Mori and Aoki \[[@CR19]\]January 2010-- December 2014Retrospective case--control, epidemiological, single-center study assessing risk factors for CDIOutpatients\
(1,914,011 patient-years examined)\
CDI cases\
Age- and sex-matched controls (*C. diff* toxin- and culture-negative)26 patients had community-acquired CDICommunity-acquired CDI: outpatient presentation with diarrhea, stool culture positive *C. diff* toxin assay^a,h^Incidence for community-acquired CDI 1.4/100,000 patient-years--84.6% of patients with community acquired CDI had prior exposure to antibiotics\
Patients with community-acquired CDI more likely to have had prior antibiotics (OR 8.12; 95% CI 2.43---26.98)Ogami et al. \[[@CR38]\]4-year period (dates not given)Single-center, retrospective hospital cohort\
*n* = 463Inpatients with antimicrobial associated diarrhea95/463 cases (20.5%) were CDICDI manifesting as antimicrobial-associated diarrhea (≥ 3 stools/day \> 48 h after-ward admission) and stool toxin positive (A and/or B)^a^----Increased ward use of antimicrobials clindamycin (OR 1.739; 95% CI 1.050--2.881; *p* = 0.032) and piperacillin (OR 1.598; 95% CI 1.006--2.539; *p* = 0.047) increased risk of CDIOshima et al. \[[@CR40]\]Published studies 1990--2016Systematic review and meta-analysis of 67 published studiesAdults and pediatric (≤ 18 years) patients receiving PPI who developed acute-onset diarrhea. Also, control group*n* = 17,217 in the test group; *n* = 286,018 in the control group\
Recurrent CDI occurred in *n* = 1279; *n* = 5459 in the control groupLaboratory confirmation of *C. diff* or clinical definition. No further detail provided----PPI use increased risk for initial CDI episode (random effects model, overall OR 2.34, 95% CI 1.94--2.82; *p* \< 0.00001)\
Age-stratified subgroup analyses: significant associations between PPI use and initial CDI episode in adults (OR 2.30, 95% CI 1.89--2.80; *p* \< 0.00001) and pediatrics (OR 3.00, 95% CI 1.44--6.23; *p* \< 0.00001)Roughead et al. \[[@CR36]\]2008--2013 (insurance database)\
1996--2014 (hospital dataset)Retrospective data from worker insurance database and a hospital in-/outpatient dataset from a single center\
1.2 million patient records examined and sequence symmetry analysis used to assess PPI use as risk factor for CDI*n* = 310 patients received PPIs and oral vancomycin (proxy indicator for CDI)--------Positive association between PPI use and CDI (adjusted sequence ratio for insurance dataset 5.40; 95% CI 2.73--8.75 and for hospital dataset 3.21; 95% CI 2.12--4.55)Sadahiro et al. \[[@CR63]\]May 2008--October 2011Prospective, single-center RCT comparing oral antibiotics and probiotics pre surgery to prevent infection\
*n* = 310Colon cancerNo change in detection of *C. diff* toxin across three treatment groups (probiotics; antibiotics; control (no probiotics or antibiotics))Assessment of *C. diff* toxin (A and B) in stool samples by RIDASCREENRates of CDI increased post-operatively in all groups (probiotic group, from 2.0% to 7.0%; antibiotic group, 5.1% to 9.1%; control group, 2.1% to 10.5%)----Sasabuchi et al. \[[@CR28]\]July 2010--March 2013Retrospective cohort study using the Japanese Diagnosis Procedure Combination database (multicenter)\
*n* = 15,651 receiving prophylaxis\
*n* = 15,651 controlsSevere sepsis and receiving stress ulcer prophylaxis within 2 days of hospital admission; propensity-matched controls did not receive prophylaxisIn propensity-matched cohort, 215 and 204 cases of CDI in the stress ulcer prophylaxis and control groups, respectivelyNot specified, but ICD-10 codes used for other definitions. CDI coded as 'complication' in medical records during hospitalization1.4% in stress ulcer prophylaxis group and 1.3% in control (*p* = 0.588)----Suzuki et al. \[[@CR23]\]April 2010--March 2012Single-center prospective cohort pre and post intensive infection control measures\
*n* = 80Hospitalized patients--Based on medical records and healthcare resource use\
New-onset nosocomial *C. diff*-associated disease*C. diff*-associated disease reduced from 0.47 cases/1000 inpatient days to 0.11 (*p* \< 0.001) after intensive infection control team interventions----Takahashi et al. \[[@CR39]\]November 2010-- October 2011Multicenter case--control and cohort study\
*n* = 1026 CDI\
*n* = 878 controlsNational Hospital Organization cohort\
Assessed for newly diagnosed CDI and matched controls (no CDI)93.9% of CDI cases developed within 48 h of hospital admissionGI symptoms, clinical suspicion of CDI and positive *C. diff* toxins^a,h,i^ from stool or *C. diff* isolation from stool cultures, or both----Risk factors for CDI development: disruption of feeding/parenteral and enteral feeding; first- and second-generation cephem antibiotics (OR 1.44; 95% CI 1.10--1.87), third- and fourth-generation cephem antibiotics (OR 1.86; 95% CI 1.48--2.33), carbapenem antibiotics (OR 1.87; 95% CI 1.44--2.42)\
Comorbidities more common in patients with CDI\
Analysis of 924 cases noted 11% mortality within 30 days of CDI onset\
Use of vancomycin reduce mortality (OR 0.43; 95% CI 0.25--0.75)\
PPIs and penicillin did not increase risk for CDIWatanabe et al. \[[@CR64]\]January--June 2005Multicenter, retrospective cohort\
*n* = 294 fecal samples submitted for *C. diff* testingHospitalized patients79/294 (5.5 cases/1000 beds monthly) were *C. diff* toxin A+*C. diff* toxin test^c^5.5 cases/1000 beds monthly, assessed for *C. diff* were found to be *C. diff* toxin A+----Yasunaga et al. \[[@CR29]\]2007--2010Retrospective database review: analysis of factors affecting *C. diff*- associated disease and outcomes of *C. diff* diarrhea after GI surgery\
Japanese Diagnosis Procedure Combination inpatient database (multicenter)\
*n* = 143,652Inpatients/GI surgical patients409 cases of *C. diff* diarrhea (0.28%)\
Higher rates in colorectal surgery (0.37%) vs. gastrectomy (0.21%) and esophagectomy (0.25%) (*p* \< 0.001)CD enterocolitic ICD-10 codeRate 0.28%\
Risk factors included: older age; higher Charlson comorbidity index; longer pre-operative LOS; non-academic center care\
In-hospital mortality higher in *C. diff* diarrhea than in non-*C. diff* diarrhea (3.4% vs. 1.6%: OR 1.83; 95% CI 1.07--3.13, *p* = 0.027)409/143,652 = 2.8/1000 patients^e^Risk factors included: older age; higher Charlson comorbidity index; longer pre-operative LOS; non-academic center care\
In-hospital mortality higher in *C. diff* diarrhea (3.4% vs. 1.6% in non-*C. diff* diarrhea: OR 1.83; 95% CI 1.07--3.13; *p* = 0.027)\
LOS attributable to post-operative *C. diff* diarrhea 12.4 days (95% CI 9.7--15.0; *p* \< 0.001)*BMT* bone marrow transplantation; *CI* confidence interval; *GDH* glutamate dehydrogenase; *GI* gastrointestinal; *HSCT* hematopoietic stem cell transplantation; *IV* intravenous; *LOS* length of stay; *OR* odds ratio; *PPI* proton pump inhibitor; *RCT* randomized clinical trial; *YIF-SCAN* Yakuly Intestinal Flora-SCAN system^a^TOX A/B QUIK CHEK^®b^C DIFF QUIK CHEK COMPLETE^®c^UNIQUICK^d^CD CHECK^e^Calculated from data available in the publication and not stated in the publication^f^XPECT C. DIFF toxin A/B^g^*C. diff* Toxin A test, Oxoid^h^ImmunoCard CD toxin A&B^i^X/pect Toxin A/B

Very few papers reported incidence in terms of cases per 10,000 patient-days; most reported observed CDI ratios (as percentages), with CDI variously defined, or prevalence within specific patient subgroups or populations (Table [1](#Tab1){ref-type="table"}). Figure [2](#Fig2){ref-type="fig"} depicts reported CDI incidence from retrospective chart reviews in different patient cohorts, where CDI was defined based on diarrhea and laboratory detection of fecal *C. difficile* toxin.Fig. 2*Clostridium difficile* infection (defined as diarrhea/CD toxin) reported in retrospective cohorts of Japanese patients. *CRC* colorectal cancer, *GI* gastrointestinal, *HSCT* hematopoietic stem cell transplantation, *IBD* inflammatory bowel disease, *pts* patients, *RA* rheumatoid arthritis. Patient numbers represent those diagnosed with *Clostridium difficile* infection

A chart review of over 22,800 inpatients at a single tertiary care center (of whom 851 were tested for *C. difficile*) reported on healthcare-facility onset CDI, defined as diarrhea and a positive toxin test (using C DIFF QUIK CHEK COMPLETE^®^) \[[@CR18]\]. The CDI prevalence was 5.5 cases/1000 patients. The incidence of healthcare-facility onset CDI was 3.11 cases/10,000 patient-days, compared with 0.2 cases/10,000 patient-days for community-onset CDI \[[@CR18]\]. The authors considered the CDI incidence (hospital- and community-onset) to be rather low, which they suggested may have been attributable to the relatively low frequency of testing for *C. difficile* and the relatively low sensitivity of the EIA toxin detection method. Another large-scale outpatient study (*n* = 2193) reported the incidence of community-acquired CDI as 1.4/100,000 patient-years (or 0.14/10,000 patient-years) \[[@CR19]\], and a study of both actively tested in- and outpatients provided an incidence of 0.8 cases/10,000 patient-days \[[@CR20]\]. A retrospective cohort study based on chart reviews at four tertiary care hospitals reported 160 patients aged at least 14 years with hospital-onset CDI, as defined according to clinical practice guidelines, giving an incidence of 1.04/10,000 patient-days (or 1.61/1000 admissions) \[[@CR21]\]. The low incidence of hospital-onset CDI compared with that reported in studies from Western countries was suggested by the authors to be a consequence of the different strains prevalent in different regions, with outbreaks of hospital-acquired CDI in Western countries being attributed to highly virulent strains that are not prevalent in Japan. The study did not explore the strains responsible for the CDI episodes at the four hospitals. The authors also suggested that the low frequency of CDI may be a consequence of the low frequency of testing for *C. difficile* \[[@CR21]\].

Few studies identified in our search described measures to control the incidence of *C. difficile* in hospitals. Although not strictly an infection control measure, the prophylactic use of pre- and probiotics has been suggested to maintain the colonic microbiota and potentially reduce the development of CDI \[[@CR22]\]. A single-center RCT of 379 patients undergoing colorectal surgery evaluated the impact of perioperative synbiotics (combination of pro- and prebiotics) on post-surgical outcomes and fecal microbiota composition, finding that patients administered synbiotics before surgery had a lower incidence of *C. difficile* in their fecal microbiota compared with control patients. The incidence of CDI was low, with only one patient in the control group developing CDI, while none in the treated group did so. The authors suggested a potential role for synbiotics in suppressing overgrowth of *C. difficile* after surgery \[[@CR22]\]. The literature search also identified a study reporting the impact of infection control interventions on CDI occurrence. A medical record-based *C. difficile*-associated disease at a single center was reported to have an incidence of 0.47 cases/1000 inpatient days, which fell to 0.11 cases/1000 patient-days after intensive infection control intervention \[[@CR23]\]. Infection control measures included carbapenem restriction and continuous instruction to the ward staff on infection control measures \[[@CR23]\].

Some of the epidemiological reports highlighted the incidence and prevalence of CDI in particular patient groups (Table [1](#Tab1){ref-type="table"}; Fig. [2](#Fig2){ref-type="fig"}). For example, in patients undergoing HSCT, the cumulative incidence of CDI was 6.2% for all patients, compared with 9.2% in the allogeneic HSCT subpopulation, 1.0% in the autologous HSCT subpopulation and 9% in a cohort of HSCT recipients who received unrelated cord blood \[[@CR24], [@CR25]\]. In a cohort of liver transplant patients, CDI-associated diarrhea occurred at a rate of 4.5% \[[@CR26]\]. Among rheumatology inpatients, CDI was observed in 0.16% \[[@CR27]\]; in a large cohort of patients with sepsis, hospital-acquired CDI was observed in 1.3% of patients without and 1.4% with ulcer prophylaxis \[[@CR28]\]. A retrospective database review of over 140,000 gastrointestinal (GI) surgery patients reported CDI (ICD-10 definition) in 0.28% of the study population, or a prevalence of 2.8 cases/1000 patients \[[@CR29]\]. In a smaller cohort study of patients with active ulcerative colitis, 40.1% tested positive for possible CDI \[[@CR30]\]. A study of pediatric patients with cancer who were hospitalized at a single center reported CDI (clinical symptoms and positivity for toxin EIA using TOXA/B QUIK CHEK) in 27% of the study population \[[@CR31]\]. The authors suggested that the high incidence of CDI compared with other studies of similar patient populations in non-Japanese settings may be because of the much longer length of stay for patients with cancer in Japan compared with other countries \[[@CR31]\].

Among the studies that reported on possible *C. difficile* colonization of patient groups was an epidemiological study of hospitalized pediatric patients. At least 1 in 10 pediatric patients harbored *C. difficile* asymptomatically, while fecal cytotoxin was found in 9% of otherwise healthy children and 23.1% of children with underlying disease \[[@CR32]\]. However, these findings should be interpreted with caution as the inclusion of patients younger than 3 years old may increase the likelihood that the diarrhea had a cause other than *C. difficile* \[[@CR33]\].

The reviewed studies included reports of both hospital and community patients. No papers were identified that specifically related to patients in long-term healthcare facilities and only one paper reported on changes in infection over time \[[@CR23]\]. Therefore, depending on the patient group and methods used to define and assess CDI, the incidence varied between 0.8 and 4.71/10,000 patient-days, while the prevalence was between 0.3 and 5.5 cases/1000 patients.

Risk Factors {#Sec10}
------------

Known risk factors for CDI include: co- and previously administered broad-spectrum antibiotics; age and comorbidities; poor infection-control practices; GI tract surgery; and gastric-acid suppressing agents \[[@CR13], [@CR34]--[@CR36]\]. Thirteen studies in our search, including a large database study representing 40% of all adult-care hospitalizations, identified risk factors for CDI in Japanese patients, which included older age, higher comorbidity index; gastric acid-suppressing proton pump inhibitors (PPIs); and a longer pre-operative LOS before GI surgery \[[@CR19], [@CR20], [@CR24]--[@CR26], [@CR29], [@CR31], [@CR32], [@CR36]--[@CR40]\] (Table [1](#Tab1){ref-type="table"}). Malignant disease and intensive care unit (ICU) stay were linked with increased risk for CDI recurrence in in- and outpatients \[[@CR20]\]. Six articles reported on the number of days spent in hospital prior to surgery or CDI diagnosis, indicating a wide variation in inpatient stay before diagnosis \[[@CR18], [@CR20], [@CR29], [@CR38], [@CR41], [@CR42]\]. The only study to formally compare pre-operative number of days in hospital for patients who did and did not develop CDI found no difference between the two patient groups, with a median (interquartile range) of 6 (3--14) days and 5 (3--8) days, respectively (*p* \< 0.001) \[[@CR29]\].

Patients undergoing HSCT are recognized to be at particular risk of infection. Allogeneic HSCT, conditioning for HSCT, acute leukemia and prolonged neutropenia in the first 30 days after HSCT may all confer an increased risk for CDI as reported in a single-center study \[[@CR24]\]. In contrast, it was noted that among allogeneic HSCT patients, treatment with total body irradiation may reduce post-transplant risk of CDI \[[@CR25]\].

A study of pediatric patients reported that tube feeding was significantly associated with higher colonization rates by toxin-positive *C*. *difficile* \[[@CR32]\].

Antibiotic use was a risk factor for *C. difficile* diarrhea in a number of studies \[[@CR19], [@CR31], [@CR37], [@CR38]\]; however, in a study of liver transplant patients, the intensity of antibiotic use (measured as use of preoperative antibiotics or the number of antibiotics used postoperatively) was not a predictor for *C. difficile* diarrhea \[[@CR26]\]. Among hospitalized pediatric patients with cancer, use of a wide variety of antibiotics (the study specified at least four different types) in the 60 days prior to CDI diagnosis was a significant risk factor for the development of CDI \[[@CR31]\].

Specific Strains Responsible for CDI {#Sec11}
------------------------------------

A review of CDI in Asia in 2013 reported that PCR ribotypes 027 and 078 were rare, while variant toxin A−/toxin B+ strains of ribotype 017 were common. Furthermore, in Japan, common ribotypes include 014, 002 and 001, and ribotype smz/018 has been implicated in widespread disease \[[@CR3]\]. The review noted that a variety of typing techniques has been used in Japan, including *tcdA* and *tcdB* detection, pulsed field gel electrophoresis (PFGE), PCR ribotyping and *slpA* typing. Although molecular typing had identified toxigenic A−B+ strains, the authors did not comment on binary (CDT) toxin assessment or *C. difficile* surveillance in Japan \[[@CR3]\].

In our literature search, 16 papers provided further details of testing methods used in Japan and described reports on the isolates and strains associated with CDI in Japanese cohorts (Table [2](#Tab2){ref-type="table"}). The methods used to detect CDI and/or detect, isolate and type *C. difficile* included stool culture and C DIFF QUIK CHEK COMPLETE^®^; stool culture, PCR ribotyping and *slpA* sequence typing; stool culture, PCR and PFGE; and rRNA-targeted RT-qPCR and multiplex PCR for toxin gene profiling. Reported methods of testing for *C. difficile* toxins included: toxin A testing by Uniquick (in 2004) \[[@CR43]\]; PCR assessment for toxin A, B and CDT genes \[[@CR44]\]; TOX A/B QUIK CHEK^®^ \[[@CR45]\]; and multiplex PCR \[[@CR46]\]. Rapid detection methods evaluated and reported in Japan include detection of GDH and toxin A/B in feces (using Immunocard^®^ and TOX A/B, respectively) \[[@CR47]\]; and detection of GDH and toxin A/B simultaneously using C DIFF QUIK CHEK COMPLETE^®^ \[[@CR41]\]. Although mass spectrometry methods have also been reported, these were not considered suitable for typing *C. difficile* \[[@CR48]\].Table 2Summary of studies describing *C. difficile* strains, test methods and assay for binary toxin in JapanReferenceStudy periodStudy designPatient population*C. diff* definitionTest methodsIsolates and strainsBinary toxinCollins et al. \[[@CR3]\]Pre-2013Narrative review and meta-analysis of 42 cohort studies on *C. diff* in Asian countriesVariousVariousIn Japan: *tcdA* and *tcdB* characterization, PFGE, PCR ribotyping and *slpA* typingPredominance of ribotype smz (018) in past decade\
Other common ribotypes: 014, 002, 001Not specifically mentioned in review of Japanese papersIwashima et al. \[[@CR44]\]April 2005--March 2008Retrospective cohort study assessing genotypic features of isolates and clinical characteristics of CDI (single center)\
*n* = 610 submitted specimensPatients with stools found positive for *C. diff* culture (*n* = 106; of which 35 excluded as asymptomatic carriers and *n* = 14 excluded for non-toxigenic strains)\
71 CDI cases assessedCDI defined as: diarrhea or colitis with toxin B positive *C. diff* and no other enteropathogenic microorganismsPCR assessment of toxins A and B and ribotypingIsolates\
A+B+CDT+: 4/71\
A+B+CDT−: 58/71\
A−B+CDT−: 9/71\
Ribotype\
A+B+CDT+: 2 were j52; 1 was nc07109; 1 was km0403\
A+B+CDT−: 19 were smz; 14 were yok; 13 were hr; 12 other\
A−B+CDT−: 6 were trf; 2 were fr; 1 was sgf\
No predominant ribotype spreading; the dominant types were smz, yok and hr (hr = equivalent to ribotype 014)\
No ribotypes 027 and 078 found in the study\
Duration of CDI longer in yok group (p \< 0.05)Incidence of CDIs with binary toxin-positive strains 5.6% (noted in non-severe CDI)Kato et al. \[[@CR43]\]February 2004--April 2004Single-center study to validate efficacy of *slpA* sequence typing\
28 samples positive for toxin A from 17 patients with *C. diff* diarrhea*C. diff* diarrhea: 22/28 samples positive by stool cultureNot specifically defined (see testing methods)Detection of toxin A using UNIQUICK\
*slpA* sequence typingAll samples except hj2-2 isolate were A+B+CDT− (positive for toxin A and toxin B but negative for binary toxin)\
smz-1 (*n* = 10) and smz-2 (*n* = 6) accounted for 73% strains\
Strain pattern suggested nosocomial infection\
Yok-1, yok-2, t25--1, hr-1 and hj2-2 identified in at least 1 patient eachBinary toxin assessedKato et al. \[[@CR49]\]2003--2007Multicenter study typing *C. diff* isolates by *slpA* sequencing160 stool samples from symptomatic patients (hospitalized with a diagnosis of antibiotic-associated diarrhea or colitis)Not specifically defined (see testing methods)\
90 stool samples were typed of which 77 were positive by culture for *C. diff*Stool culture: PCR for toxins A and B, and CDT\
PCR ribotyping and *slpA* sequence typingSmz sequence type was dominant and detected by culture and/or typing in 61/99 stool samples positive for toxic culture and/or direct *slpA* sequencing (smz in 62%; smz-01, smz-02, smz-04)\
One isolate type gc8 corresponded with PCR ribotype 027 BI/NAP1/027); no PCR ribotype 078 found\
Direct typing from DNA extracted from stool samples: 77/90 were positive for *C. diff* and typing results agreed with isolated strain typing\
*slpA* subtypes smz-01, -02 and -04 found in 51/86 (59%) of stool samples that were *tcdB*-positive *C.diff* cultured and in 67% of stool where direct typing could be obtainedOf 87 isolates, 75 (86%) were A+B+ and 12 (14%) were A−B+; 3 A+B+ isolates were positive for PCR detecting the binary toxin gene (A+B+CDT+)Kawada et al. \[[@CR47]\]October 2009--January 2010Single-center study evaluating a single kit for rapid detection of GDH and toxin A/B in feces (as diagnosis of *C. diff* infection)60 specimens from 60 patients with antibiotic-associated diarrhea*C. diff* culture was reference method\
*C. diff* evaluated 28 inpatients diagnosed as having CDIEvaluation of C DIFF QUIK CHEK COMPLETE^®^ vs. GDH detection by ImmunoCard and toxin A/B detection by TOX A/BThe kit had GDH sensitivity 100%; specificity 93.3%; negative predictive value 100%\
Kit had Toxin A/B sensitivity 78.6%, specificity 96.9% compared with toxigenic culture (culture B positive)\
The 22/23 specimens that were dual positive for GDH and toxin A/B were culture positive\
Dual negatives by the kit were *C. diff* culture negativeNot reportedKikkawa et al. \[[@CR65]\]January--June 2005Multicenter study looking at prevalence of A−/B+ strains in fecal samples submitted for *C. diff* tests*C. diff* isolated in 159/332 specimensAs per test methodsCulture\
PCR analysis of toxigenic typing\
Genotyping by PCR, ribotyping and PFGE332 sample; *C. diff* isolated from 159: 137 strains (41% examined specimens and 86% of isolated *C. diff*) were A+B+; 10 (3% and 6%) were A−B+ and 12 (4% and 8%) were A−B−\
Therefore 10 (6.3%) of 159 *C. diff* strains were A−B+\
All 10 A−/B+ strains had identical pattern by PCR ribotypingNot reportedKobayashi et al. \[[@CR45]\]April 2008--March 2009Single-center retrospective study to test/validate the 3-day rule for ordering a *C. diff* toxin test in Japanese patients1597 stool cultures from 992 patients; 880 CD toxin tests performed in 529 patients\
83 species from 81 specimens considered enteric pathogensAs per test methodsCD toxin by TOX A/B QUIK CHEK^®^Rate of positive stool culture in different patient groups: 14.2% outpatients; 3.6% inpatient ≤ 3 days; 1.3% inpatients ≥ 4 days\
Respective CD toxin positive test rates: 1.9% outpatients; 7.1% inpatient ≤ 3 days; 8.5% inpatients ≥ 4 days\
The study validates the 3-day rule: the rule can be used to estimate the pre-test probability of a stool microbiological testNot reportedKunishima et al. \[[@CR66]\]February 2003--February 2006Single-center study of antimicrobial susceptibility of *C. diff* isolatesStudied 157 *C. diff* isolates from patients with diarrhea and probable CDI--Antimicrobial sensitivity of isolates: broth microdilution method to determine MICs of 15 drugsFound no strains resistant to either metronidazole or vancomycinNot reportedKuwata et al. \[[@CR46]\]April 2012--March 2013Single-center study of molecular epidemiology and antimicrobial sensitivity of *C. diff* isolates*C. diff* isolates (*n* = 130)--Toxin genotypes; MLST and eBURST analysis\
Results compared with 9 strains previously analyzed by PCR ribotyping\
Strains identified by C DIFF QUIK CHEK COMPLETE^®^; multiplex PCR for toxigenic type95 toxigenic strains (73%), including 7 A−B+CDT− and 3 A+B+CDT+ (23 sequence types)\
35 (27%) non-toxigenic strains (12 sequence types)\
Sequence type (ST)17 was most common (21.8%)\
MLST and eBURST showed 139 strains belonged to 7 groups and singletons; most A+B+CDT− (89/91, 98%) were classed into group 1\
MLST and eBURST suggest most A+B+CDT− strains (including ST17, ST2, ST8) may be derived from ST28This study reported a prevalence of A−B+CDT− (5%) and A+B+CDT+ (2%), which is considered low compared with MLST studies in China and SpainMikamo et al. \[[@CR52]\]May 2012--May 2015Phase 3, multicenter (35 in Japan), double-blind RCT, *n* = 93\
CDI diagnosed by EIA (97%) and stool culture (3%)Adults (≥ 18 years) prescribed SOC antibiotics for CDI with planned duration 10--14 days\
Inpatients, *n* = 86; ≥ 65 years, *n* = 85Diarrhea (≥ 3 loose stools/24 h) + positive stool test for toxigenic *C. diff*Cell culture cytotoxicity assays, stool culture with toxigenic strain typing, stool culture with toxin detection from *C. diff* isolates or commercially available assays (ELISA/PCR with ≥ 94% specificity)54 strains identified from culture. PCR ribotypes were 052 (28%), 018 (19%), 002 (15%), 369 (9%), 159 (6%), 005 (4%), 173 (4%), 012 (2%), 014 (2%), 043 (2%), 056 (2%), 103 (2%), 212 (2%), 235 (2%), 254 (2%), 632 (2%). 052 isolated from 11 of 35 sites and 018 isolated from 9 of 35 sites--Mori et al. \[[@CR42]\]12-month period in 2010Single-center retrospective analysis of stool culture database to study extent/ reasons for incorrect diagnosis of CDI*n* = 975 stool culture samplesDefinitions: toxigenic *C. diff*, *C. diff* with any toxin gene; CDI, diarrhea plus a toxigenic *C. diff* isolatePCR assay of toxin gene A, B and binary\
PCR ribotyping\
Incidence of healthcare-facility onset CDI (within 48 h) estimated at 1.6 cases/10,000 patient-daysThe prevalence rate of toxigenic *C. diff* in all stool cultures was 13% (127/975)\
177 *C. diff* isolates detected of which 127 were toxigenic: 124 (70%) A+B+; 3 (1.7%) A−B+\
The most common ribotype was 369 (21.6%), with 018 (10.8%); 014/020 and 002 were 9.9% each\
Clinically important isolates such as 027 and 078 were not identified\
58 (45.7%) with toxigenic *C. diff* had unformed stool; incidence of CDI was 1.6/10,000 patient-days\
But of these 58 cases, 40 were not diagnosed in routine testing due to lack of clinical suspicion (24.1%) or a negative *C. diff* toxin assay result (44.8%)Among A+B+, 12/177 (6.8%) were CDT+Oka et al. \[[@CR67]\]2002--2005Two-center study of molecular characterization of *C. diff* isolates from single, relapse and recurrent cases*n* = 73 clinical isolates of *C. diff*\
(*n* = 20 isolates from 20 single infections; *n* = 53 isolates from 20 recurrent cases)As test methodsPFGE and PCR ribotyping, and PCR toxin detection11 ribotypes\
Of 73 strains studied, 67 strains (91.8%) A+B+; 2 were toxin A−, B+ \[B+\] (2.7%); 4 (5.4%) were A−B−\
80% of relapses were caused by the same strain as the first infection; 20% were due to a different strain--Sawabe et al. \[[@CR50]\]November 1999--October 2004Molecular analysis of *C. diff* isolates linked with diarrhea or colitis at a single center*n* = 148 isolatesAs test methodsPCR and PFGE ribotyping\
Toxin (A, B and CDT) determined by PCR26 PCR ribotypes among 148 isolates\
Shift from predominant ribotype a (15/33; 45% in 2000) to ribotype f (identical to smz) (18/28; 64% in 2004)\
PFGE allowed further sub-classification: f isolates were of 4 types and 11 subtypes\
Only one ribotype 027 recovered110/148 (74%) A+B+CDT−; 33/148 (22%) A−B+CDT−; 5/148 (3%) A+B+CDT+Senoh et al. \[[@CR51]\]April 2011--March 2013 for non-outbreak\
2010 and 2009 outbreak dataMulticenter study to assess *C. diff* isolates in Japan*n* = 120 *C. diff* isolates during a non-outbreak season; *n* = 18 and *n* = 21 isolates from hospitals during outbreaksAs test methodsToxin detection and typing by PCR120 outbreak isolates: 80% were A+B+CDT−, 15.8% were A−B+CDT−; 4.2% A+B+CDT+\
PCR-ribotype smz (A+B+CDT−) accounted for 34.2% isolates\
All A−B+CDT− isolates were PCR ribotype trf\
Non-outbreak isolates: Japan ribotypes smz (018) and ysmz 39.2%, and Japan ribotype trf 15.8%\
Types smz/ysmz also predominated in outbreaks\
5 binary toxin-positive isolates (only 1 was 027 and 1 was 078)\
All trf isolates were A−B+ (new ribotype 369)\
High rates of resistance to antimicrobials observed in the 018 isolatesSee 'Isolates and strains'Shimizu et al. \[[@CR41]\]April 2013--March 2014Study to evaluate differences in disease severity score according to toxigenic culture testing and GDH/EIA testing (single center)*n* = 334 fecal samples from patients with diarrheaSevere CDI defined as pseudomembranous colitis on endoscopy, admission to ICU or any two of age \> 60 years, temperature \> 38.3 °C, serum albumin \< 2.5 g/dL, white cell count \> 15,000 cells/mm^3^Simultaneous detection of GHD and toxins A/B by C DIFF QUIK CHEK COMPLETE^®^252 GDH-negative/EIA toxin-negative (i.e. no CDI)\
82 GDH-positive, of which 25 were EIA-positive (CDI) and 57 EIA toxin-negative (equivocal cases)\
When toxins were detected in the initial screening test (GDH-positive/EIA toxin-positive), cases were more severe than in those only identified after toxigenic culture--Yuhashi et al. \[[@CR68]\]Retrospective assessment of cases tested for *C. diff* diarrhea (single center)\
*n* = 68As test methodsEIA testing for *C. diff* diarrhea (C DIFF QUIK CHEK COMPLETE^®^)\
Patients grouped as toxin-positive stool; toxin-negative/toxin-positive isolate; dual toxin negative (stool and isolate)39 toxin-positive; 14 toxin-positive isolate group; and a dual toxin-negative stool and isolate group *n* = 15. All cases confirmed to be GDH positive by EIA\
Toxin-negative stool specimens associated with shorter diarrhea duration--*A+B+CDT+* toxin A-positive toxin B-positive, binary toxin positive strain; *A+B+CDT−* toxin A-positive, toxin B-positive, binary toxin negative strain; *A−B+CDT−* toxin A-negative, toxin B-positive, binary toxin negative strain; *EIA* enzyme immunoassays; *GDH* glutamate dehydrogenase; *ICU* intensive care unit; *MLST* multilocus sequence typing; *PFGE* pulsed-field gel electrophoresis; *RCT* randomized clinical trial; *slpA* surface-layer protein A encoding gene; *SOC* standard of care

Our literature review (Table [2](#Tab2){ref-type="table"}) suggests that most *C. difficile* isolates associated with infection in Japan produce both toxins A and B. Available studies suggest a low prevalence of binary toxin-positive (CDT+) strains---between 0 and 6.8% reported across studies \[[@CR19], [@CR44], [@CR46], [@CR49]--[@CR51]\]. A small study from 2015 found that outbreak and non-outbreak isolates were predominantly smz/ysmz (by *slpA* typing) and that of five binary toxin-positive strains, one was ribotype 027 and one 078 \[[@CR51]\]. Individual papers appear to support the conclusion that ribotypes 027 and 078 are rare in Japan \[[@CR44], [@CR49], [@CR50]\], and that smz/018, yok, 002, 014 and 369 (trf by*slpA* typing) are common \[[@CR3], [@CR42]--[@CR44], [@CR46], [@CR49]--[@CR51]\]. A recently published substudy of a global RCT that isolated 54 strains of toxigenic *C. difficile* (by EIA/PCR assays) from the stool cultures of 93 hospitalized patients at 35 sites in Japan appeared to corroborate this finding \[[@CR52]\]. The most common PCR ribotypes were 052 (28% of isolates), 018 (19% of isolates), 002 (15% of isolates) and 369 (9% of isolates), and 052 was considered to be an 'established' strain, as it was widely distributed across Japan. Ribotypes 027 and 078 were not isolated in the substudy \[[@CR52]\].

Recurrence {#Sec12}
----------

Twelve publications reported on CDI recurrence (Table [3](#Tab3){ref-type="table"}) \[[@CR18], [@CR21], [@CR24]--[@CR26], [@CR31], [@CR39]--[@CR42], [@CR44]\], with rates in studies that included specific definitions of recurrence ranging from 3.3% in 30 HSCT patients \[[@CR24]\] to 27.3% in a cohort of 11 liver transplant recipients with CDI \[[@CR26]\]. The time period over which recurrence was defined or assessed varied widely from 14 to 365 days after the initial CDI episode \[[@CR18], [@CR21], [@CR24], [@CR25], [@CR31], [@CR44]\]. One retrospective chart review of 242 liver transplant recipients, 11 of whom developed CDI, reported recurrence in 2 of 8 patients who received vancomycin \[[@CR26]\]; no analysis of risk was made in relation to the choice of treatment for CDI. A retrospective cohort study based on chart reviews of hospital-onset CDI cases at four teaching hospitals found that neither the severity of CDI nor adherence to clinical practice guidelines affected the risk of CDI recurrence \[[@CR21]\]. In a retrospective study, multivariate analysis identified malignant disease (*p* = 0.03) and ICU hospitalization (*p* = 0.049) as risk factors for CDI recurrence within 8 weeks of the previous CDI episode \[[@CR20]\]. A systematic review and meta-analysis of published studies reported that use of PPIs was significantly associated with recurrent CDI (pooled OR 1.73, 95% CI 1.39--2.15; *p* = 0.02) (Table [3](#Tab3){ref-type="table"}) \[[@CR40]\].Table 3Incidence of, and risk factors associated with, *C. difficile* infection recurrence in Japanese patient populationsReferencePatient populationTreatment of initial CDIDefinition of recurrenceRecurrenceRecurrence risk factorsAkahoshi et al. \[[@CR24]\]HSCT (*n* = 102 autologous; *n* = 206 allogeneic); *n* = 30 with CDIOral metronidazole (500 mg three-times daily, 10--14 days)New episode of diarrhea and positive toxin EIA within 365 days after first episode of CDI1/30 (3.3%) within 100 days after HSCTNRDaida et al. \[[@CR31]\]Pediatric patients (aged 0--19 years) admitted to hospital with cancerOral metronidazole (30 mg/kg) for \> 10 days until resolution of symptoms and neutrophil recovery to \> 500/μLPresence of CDI 2 weeks after resolution of primary CDI symptoms13/51 (26%)Statistical tests not performed. Recurrence more common in younger age (0--3 years; 9/13, 69%) than older children (19/38, 50%)Hashimoto et al. \[[@CR26]\]Retrospective chart review (single center) of 242 living donor liver transplant recipients (adults)\
*n* = 11 with *C. diff* diarrheaOral vancomycin (*n* = 8; dose not given) or conservative management (no detail given)No definition given, but patients assessed from hospital admission to 3 months after transplant3/11 (27.3%); 2/8 (25%) in patients who received vancomycinNRHikone et al. \[[@CR20]\]In- and outpatient samples tested for *C. diff* (*n* = 2193 samples)\
*n* = 76 with healthcare-associated CDIOral metronidazole or vancomycin (doses not given) for median 14 days (range 6--52 days)New episode of CDI within 8 weeks from the previous episode; diagnosis based on presence of diarrhea and positive toxin EIA14/76 (18.4%)Univariate analysis: no risk factors identified\
Multivariate analysis: malignant disease (OR 7.98; 95% CI 1.22--52.2; *p* = 0.03) and ICU hospitalization (OR 49.9; 95% CI 1.01--2470; *p* = 0.049)Honda et al. \[[@CR18]\]CDI cases in a non-outbreak setting\
*n* = 126 with CDI (86.5% were healthcare-facility onset CDI)Oral metronidazole (500 mg three-times daily), oral vancomycin (125 mg or 500 mg four-times daily), combination oral metronidazole (500 mg three-times daily) plus vancomycin (125 mg or 500 mg four-times daily), combination oral metronidazole plus rectal vancomycin, combination oral and rectal vancomycin, or no treatment (stop unnecessary antimicrobials)New episode of diarrhea and positive toxin assay within 30 days since last date of completing therapy for first CDI episode8/126 (6%)NRHosokawa et al. \[[@CR25]\]Allogeneic HSCT patients (135 unrelated CBT; 39 unrelated BMT and 27 related PBSCT)\
*n* = 17 with *C. diff* diarrheaOral metronidazole or oral vancomycin (dosage and duration not given)New episode of diarrhea and positive toxin test within 8 weeks after improvement of first properly treated episode0NRIwashima et al. \[[@CR44]\]CDI cases in a hospital setting\
*n* = 71 consecutive patients with CDINo formal regimens specified; 3 patients received treatment prior to recurrent CDI. Vancomycin mentioned (total dose range 6--12 g given for range of 1--28 days)New CDI episode within 2 months after recovery from previous CDI episode9/71 (12.7%)NRKobayashi et al. \[[@CR21]\]Patients aged ≥ 14 years with hospital-onset CDI, *n* = 160Metronidazole (*n* = 88, 55%), vancomycin (*n* = 52, 33%), metronidazole + vancomycin (*n* = 10, 6.3%), no antimicrobial (*n* = 10, 6.3%). Doses and duration of therapy not specifiedAccording to SHEA/IDSA 2010 guidelines \[[@CR69]\] -- re-emergence of CDI symptoms, according to infectious disease physician judgment, ≤ 4 weeks after completion of treatment for initial CDI episode23/160 (14%)Recurrence did not differ according to severe/non-severe CDI or according to whether treatment adhered/did not adhere to clinical guidelinesMori et al. \[[@CR42]\]Stool culture database\
*n* = 58 cases with CDIVancomycin or metronidazole (dosage and duration not given)No definition given, but recurrence recorded within 60 days following symptom onset3/58 (5.2%)NROshima et al. \[[@CR40]\]Adults and pediatric (≤ 18 years) patients receiving PPI who developed acute-onset diarrhea (*n* = 17,217). Also, control group (*n* = 286,018)\
Recurrent CDI (reported in 9 studies) occurred in *n* = 1279; *n* = 5459 in the control group--Not given in this systematic review and meta-analysis of published studies, but based on recurrence, as reported in published studies. CDI presence based on laboratory confirmation of *C. diff* or clinical definition--PPI use increased risk for recurrent CDI (pooled OR 1.73, 95% CI 1.39--2.15; *p* = 0.02)Shimizu et al. 2015 \[[@CR41]\]Patients in a hospital setting with diarrhea (*n* = 334 fecal samples)\
*n* = 28 patients with severe CDIMetronidazole, vancomycin (dosage and duration not given) or no treatmentNo definition given and duration of assessment not detailedOverall: 7/28 (25%); 5/16 (31.3%) in patients with GDH-positive/EIA toxin-positive test and 2/12 (16.7%) in patients with initial GDH-positive/EIA toxin-negative test, but who had confirmed positive toxigenic cultureNo difference in incidence of recurrence between the two groups (*p* = 0.662)Takahashi et al. \[[@CR39]\]National Hospital Organization cohort\
Assessed for newly diagnosed CDI (*n* = 878 patients) and matched controls (no CDI)Metronidazole, vancomycin (dosage and duration not given) or no treatmentNo definition given, but recurrence assessed and recorded within 30 days of initial CDI episode34/714 (4.8%) among patients treated for CDINR*BMT* bone marrow transplantation, *CBT* cord blood transplantation, *CI* confidence interval, *EIA* enzyme immunoassays, *HSCT* hematopoietic stem cell transplantation, *ICU* intensive care unit, *NR* not recorded, *OR* odds ratio, *PBSCT* peripheral blood stem cell transplant, *PPI* proton pump inhibitor, *SHEA/IDSA* Society for Healthcare Epidemiology of America and Infectious Disease Society of America

Healthcare Utilization {#Sec13}
----------------------

A large retrospective chart review of 22,863 patients by Honda et al. reported a median LOS among 126 CDI cases of 41.5 days (17.5 days before and 18 days post-CDI diagnosis) \[[@CR18]\]. The sparsity of available LOS data did not allow any analysis of trends for CDI-related LOS over the years examined. The adjusted attributable LOS and costs related to CDI were reported from one large database study of 143,652 hospitalized patients \[[@CR29]\]. There were 409 cases of CDI with the infection contributing to a LOS increase of 12.4 days (95% CI 9.7--15.0; *p* \< 0.001) and a cost increase of US\$6576 (95% CI 3753--9398; *p* \< 0.001) compared with control patients who did not develop CDI. However, of note, this study included patients who had undergone specific surgical procedures and had CDI identified using diagnostic codes rather than by diagnostic tests \[[@CR29]\], which could potentially lead to inaccurate identification of CDI.

Cases of CDI may require patient transfer to the ICU. The study by Honda et al. found that 9.5% of 126 CDI cases needed ICU admission \[[@CR18]\]. There were 65 (51.6%) patients who were classified as having severe CDI, using the severity assessment score developed by Zar et al. \[[@CR53]\]; three patients (2.4%) underwent CDI-related colectomy/diverting loop ileostomy because of critical illness or failure of medical therapy. Another retrospective chart review based on stool samples from in- and outpatients at a single hospital identified 76 patients with hospital-onset CDI, with three (3.9%) cases requiring ICU care \[[@CR20]\].

Mortality {#Sec14}
---------

All-cause mortality within 30 days ranged from 3.4 to 15.1% \[[@CR18], [@CR20], [@CR21], [@CR29], [@CR39]\]. Honda et al. reported that mortality was associated with an increased Zar severity score \[[@CR18]\]. Of note, the Zar severity criteria will score a patient 1 point (2 points are defined as severe CDI) based only on age 60 years or older \[[@CR53]\], and the median age of patients in the Honda et al. study was 78 years \[[@CR18]\]. A multicenter retrospective cohort study of 160 hospitalized patients with CDI reported 30-day all-cause mortality of 13%, and found no significant difference between the mortality rate among patients with severe and non-severe CDI, or among those whose treatment adhered and did not adhere to clinical practice guidelines \[[@CR21]\]. At 90 days, all-cause mortality among CDI cases was reported as 14.5% in one retrospective chart review \[[@CR20]\]. Hosokawa et al. \[[@CR25]\] concluded that, among patients who underwent unrelated cord blood transplantation, overall survival at 2 years was no different for those who developed CDI than for those who did not (42 vs. 46%, respectively; *p* = 0.77). One database study demonstrated that inpatient mortality was significantly higher in CDI patients than in those without CDI (3.4 vs. 1.6%; *p* = 0.008) \[[@CR29]\], although the results of this study should be viewed with caution owing to the reliance on recorded diagnoses of CDI from administrative databases (which are less well validated than those in prospective cohorts or registries, for example), the inclusion of only patients undergoing GI surgery, and the loss of many patients from the propensity score-matched analysis. The use of vancomycin was associated with reduced mortality (OR 0.43; 95% CI 0.25--0.75) in a multicenter, case--control and cohort study of 1026 CDI patients \[[@CR39]\].

Discussion {#Sec15}
==========

This systematic literature review identified 55 papers providing insights into the rates of CDI, patient groups affected and impact of CDI in Japan. Most of the studies were retrospective data reviews, and many focused on patients with suspected CDI, and the rates and prevalence of CDI in those groups. Fewer studies reported overall rates of hospital- and community-acquired CDI. Nevertheless, the current literature suggests that hospital-onset CDI in Japan occurs at an incidence of 0.8--4.7 cases/10,000 patient-days; lower than that reported in Europe for winter 2012--2013 (country range 0.7--28.7/10,000 patient bed-days), and similar to the US for hospital-onset CDI in 2013 (6.0/10,000 patient-days for laboratory-identified CDI and 4.4/10,000 patient-days for traditional surveillance-detected CDI) \[[@CR54], [@CR55]\]. However, direct comparisons between studies are difficult owing to differences in design, population size and detection methods used. The prevalence of CDI in Japan (0.3--5.5/1000 patient admissions) was lower than that in a US Veterans Health Administration (VHA) report from 2014, which recorded that from October 2010 to June 2012, CDI prevalence at admission was between 5.3 and 6.9/1000 admissions, in settings where 50% of hospitals used nucleic acid amplification tests \[[@CR56]\]. An analysis of US VHA data for February 2012 to January 2014 reported a pooled CDI admission prevalence rate of 0.38/100 admissions \[[@CR57]\].

CDI in Japan appears to have similar epidemiology to that in South Korea, although distinct from regions of South Asia \[[@CR3]\]. There are a number of factors that contribute to the unique epidemiology of CDI in Japan. First, if testing for CDI is not conducted, this makes data-gathering on both the rate of testing and test results difficult. While there is a national surveillance program for infectious diseases in Japan, there is no national *C. difficile* screening program. Methods of testing are also an important consideration. Indeed, datasets from CDI surveillance programs highlight that country-to-country variations in CDI incidence largely reflect differences in surveillance methods and how rigorously CDI is investigated in testing strategies \[[@CR54]\]. This literature review highlights that testing, typing and laboratory methods for assessment and diagnosis of CDI have evolved in Japan in recent years, with new methods continuing to be evaluated against established methods. However, some authors have noted that many reports of CDI epidemiology in Japan have relied on insensitive testing methods, such as EIA toxin tests \[[@CR16]\]. While more sensitive nucleic acid amplification tests are recommended in clinical practice guidelines for the detection of *C. difficile* \[[@CR7]\], these are not yet subject to reimbursement in Japan and are therefore not widely used, thus reliance on EIA remains common in clinical practice. It could be argued that a low detection frequency, as seen for CDI toxin tests in stool samples, may in fact reflect a low disease burden, as demonstrated by Shimizu et al., who reported that patients with positive EIA toxin tests in stools had more severe CDI than those patients with negative stool toxin tests who then had positive cultures \[[@CR41]\]. It is recognized that CDI is under-diagnosed in many regions and countries because of a combination of absence of clinical suspicion and suboptimal laboratory diagnostics \[[@CR54]\]. This may also be the case in Japan, although no papers in this search specifically focused on reporting under-diagnosed or missed CDI cases.

Increased LOS is both a risk factor for, and an outcome of, CDI \[[@CR29]\]. A notable factor in Japan is the general tendency for a longer LOS compared with many other countries, which may have an impact on, and thus affect, CDI risk and rates \[[@CR58]\]. Incidence of CDI is typically presented as per patient-days (i.e. patient-bed days or inpatient days) and it is important to understand the differences in overall LOS in different geographic regions when comparing incidence data. National statistics from Japan show that in 2014 mean LOS was 31.9 days for all patients and 41.7 days in those ≥ 65 years \[[@CR59]\], whereas the comparable 2014 statistics from the USA were 4.6 days for all patients (not restricted to those with CDI), 5.2 days for patients aged 65--74 years and 5.3 days for those aged 75 years and over \[[@CR60]\]. This suggests that if follow up was similar between nations, roughly eight times more patients would be included in the US study compared with a Japanese study to yield 10,000 patient-days as the denominator. Given the lengthy LOS in Japan, as in studies from other countries, rates of, and risks for, CDI in Japanese patients are increased by factors such as older age, presence of comorbidities, certain clinical/surgical procedures and exposure to drug therapies, including antibiotics \[[@CR1]\]. We found that CDI recurrence similarly depended on a variety of factors, including clinical circumstances and settings, ranging from 3.3% in HSCT patients \[[@CR24]\] to 27.3% in liver transplant patients \[[@CR26]\]. We found very few data on risk factors for CDI recurrence, such as the choice of treatment for initial CDI. One study identified malignant disease and ICU hospitalization as risk factors for CDI recurrence \[[@CR20]\], although the broad CIs cited for both (Table [3](#Tab3){ref-type="table"}) suggest that analysis of risk factors in a larger population is required. As previously established \[[@CR1]\], one systematic review and meta-analysis identified in our review revealed a strong association between PPI use and the risk for initial and recurrent CDI in both adults and children \[[@CR40]\].

Most CDI cases in Japan are caused by strains of *C. difficile* that produce both toxins A and B. Recent reviews of CDI in Asia, which are supported by our literature review, showed that ribotype smz/18 (or 018) predominates in Japan \[[@CR3]\] and that ribotype trf/369 is gaining prominence in the country \[[@CR61]\]. Several of the studies we reviewed confirmed a low prevalence of ribotypes 027 and 078 in Japan. It has been postulated that the low prevalence of these highly virulent strains that cause sporadic outbreaks in Western countries may account for the low general incidence of CDI in Japan \[[@CR21]\]. Further, we found that recent papers reporting on CDI strain and ribotype increasingly included a binary toxin assessment, although CDT+ *C. difficile* was rare in Japan \[[@CR42], [@CR46]\].

There are a number of limitations to this review. Most reports on CDI epidemiology in Japan included here were based on hospital cohort data, and were often (in 32 of 55 studies) single-site reports concerning either inpatients or patients discharged from hospital to the community. We did not find papers reporting on CDI rates in long-term care facilities, although, given the prolonged LOS reported in studies in our review, some hospitals may 'replace' long-term care facilities in some instances. There was a large degree of heterogeneity in relation to the definition of initial and recurrent CDI in the studies included in our review. This hampered our ability to evaluate the epidemiological data in a consistent manner and reduced the potential to draw robust conclusions. Although the papers reviewed spanned more than a 10-year period, there were no data describing local infection changes over time. However, we did find sporadic snapshots of CDI in certain patient subgroups and cohorts. Our review was further limited by a lack of information relating to the rate of CDI testing and no data on community-associated CDI.

Future studies and surveillance are necessary to gather data on the numbers and types of patients affected by, or at risk of, CDI in Japan. Furthermore, data on the clinical impact of CDI are important for management and resource planning, and to ensure optimal patient care and outcomes.

Conclusion {#Sec16}
==========

The current literature offers some insights into the evolving epidemiology of CDI in Japan, yet highlights a number of unresolved questions. Notably, heterogeneity in the CDI definitions in the studies we reviewed limited our ability to draw robust conclusions. With the availability of newer diagnostic tools and release of clinical practice guidelines for CDI, there is a need to undertake more comprehensive and coordinated studies and surveillance of both CDI cases and *C. difficile* isolates to map current trends, review the impact of infection control measures, increase knowledge of risk factors, and more fully understand the extent and impact of hospital-onset CDI in Japanese patient populations today.
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